Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.56 |
| ▸ | CHRNA10 | Q9GZZ6 | 4/20 | 0.56 |
| ▸ | CHRNA9 | Q9UGM1 | 4/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 2/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3309684 | 1.00 | CHRNA7 (0.56) | CHRNA7CHRNA10CHRNA9TDP1L3MBTL1 | |
| SCHEMBL13334183 | 0.99 | CHRNA7 (0.55) | CHRNA7CHRNA10CHRNA9TDP1L3MBTL1 | |
| Bromide SCHEMBL3309638 | 0.86 | TDP1 (0.55) | CHRNA7TDP1L3MBTL1HRH1TBXAS1 | |
| Bromide SCHEMBL3313475 | 0.84 | TDP1 (0.54) | CHRNA7CHRNA10CHRNA9TDP1L3MBTL1 | |
| Bromide SCHEMBL3311904 | 0.84 | TDP1 (0.54) | CHRNA7CHRNA10CHRNA9TDP1L3MBTL1 | |
| SCHEMBL13334235 | 0.83 | TDP1 (0.55) | TDP1L3MBTL1HRH1TBXAS1CYP2A6 | |
| SCHEMBL13334285 | 0.82 | HRH1 (0.58) | CHRNA7TDP1L3MBTL1HRH1TBXAS1 | |
| Bromide SCHEMBL3313796 | 0.81 | TDP1 (0.56) | CHRNA7TDP1L3MBTL1HRH1TBXAS1 | |
| Bromide SCHEMBL3312616 | 0.81 | TDP1 (0.56) | CHRNA7TDP1L3MBTL1HRH1TBXAS1 | |
| SCHEMBL4400676 | 0.80 | CHRNA7 (0.62) | CHRNA7CHRNA10CHRNA9HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140371266-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIV KENTUCKY RES FOUND (US) | 2014-12-18 | — | — | US | claimed |
| US-8846937-B2 | Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-09-30 | — | — | US | claimed |
| US-20100113511-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-05-06 | — | — | US | claimed |
| WO-2007149392-A1 | MONO QUATERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS | UNIVERSITY OF KENTUCKY (US) | 2007-12-27 | — | — | WO | claimed |
| US-9550753-B2 | Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2017-01-24 | — | — | US | disclosed |
| US-20140371266-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIV KENTUCKY RES FOUND (US) | 2014-12-18 | — | — | US | disclosed |
| US-8846937-B2 | Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-09-30 | — | — | US | disclosed |
| US-20100113511-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2007149392-A1 | MONO QUATERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS | UNIVERSITY OF KENTUCKY (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113511-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | CHRNA2, CHRNA4, CHRNA5 | CHRNA7 8/4885CHRNA10 4/4885CHRNA9 13/4885 |
| US-20140371266-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | CHRNA2, CHRNA4, CHRNA5 | CHRNA7 8/4885CHRNA10 4/4885CHRNA9 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.